Lessee, Operating Lease, Liability, to be Paid, Year Three of Enlivex Therapeutics Ltd. from 30 Jun 2020 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Enlivex Therapeutics Ltd. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three in USD history and change rate from 30 Jun 2020 to 30 Jun 2025.
  • Enlivex Therapeutics Ltd. Lessee, Operating Lease, Liability, to be Paid, Year Three for the quarter ending 30 Jun 2025 was $99,000, a 15% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Three, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Three, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Three (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $99,000 -$18,000 -15% 30 Jun 2025 6-K 29 Aug 2025 2025 Q2
Q4 2024 $121,000 -$95,000 -44% 31 Dec 2024 20-F 30 Apr 2025 2024 FY
Q2 2024 $117,000 30 Jun 2024 6-K 30 Aug 2024 2024 Q2
Q4 2023 $216,000 -$487,000 -69% 31 Dec 2023 20-F 30 Apr 2024 2023 FY
Q4 2022 $703,000 -$120,000 -15% 31 Dec 2022 20-F 10 Apr 2023 2022 FY
Q4 2021 $823,000 +$592,000 +256% 31 Dec 2021 20-F 29 Apr 2022 2021 FY
Q4 2020 $231,000 31 Dec 2020 20-F 30 Apr 2021 2020 FY
Q2 2020 $135,000 30 Jun 2020 6-K/A 13 Oct 2020 2020 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.